| Targeted therapies for triple-negative breast cancer: combating a stubborn disease M Kalimutho, K Parsons, D Mittal, JA López, S Srihari, KK Khanna Trends in pharmacological sciences 36 (12), 822-846, 2015 | 305 | 2015 |
| Adenosine 2B receptor expression on cancer cells promotes metastasis D Mittal, D Sinha, D Barkauskas, A Young, M Kalimutho, K Stannard, ... Cancer research 76 (15), 4372-4382, 2016 | 159 | 2016 |
| Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer M Kalimutho, G Del Vecchio Blanco, S Di Cecilia, P Sileri, M Cretella, ... Journal of gastroenterology 46, 1391-1402, 2011 | 153 | 2011 |
| Mechanisms of genomic instability in breast cancer PHG Duijf, D Nanayakkara, K Nones, S Srihari, M Kalimutho, KK Khanna Trends in molecular medicine 25 (7), 595-611, 2019 | 139 | 2019 |
| Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis J Jeffery, D Sinha, S Srihari, M Kalimutho, KK Khanna Oncogene 35 (6), 683-690, 2016 | 135 | 2016 |
| LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer T Boulding, RD McCuaig, A Tan, K Hardy, F Wu, J Dunn, M Kalimutho, ... Scientific reports 8 (1), 73, 2018 | 134 | 2018 |
| Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer M Kalimutho, S Di Cecilia, G Del Vecchio Blanco, F Roviello, P Sileri, ... British journal of cancer 104 (11), 1770-1778, 2011 | 127 | 2011 |
| AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer PD Dunne, DG McArt, JK Blayney, M Kalimutho, S Greer, T Wang, ... Clinical Cancer Research 20 (1), 164-175, 2014 | 114 | 2014 |
| Natural Killer Cells Are Essential for the Ability of BRAF Inhibitors to Control BRAFV600E-Mutant Metastatic Melanoma L Ferrari de Andrade, SF Ngiow, K Stannard, S Rusakiewicz, M Kalimutho, ... Cancer research 74 (24), 7298-7308, 2014 | 110 | 2014 |
| ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer S Van Schaeybroeck, M Kalimutho, PD Dunne, R Carson, W Allen, ... Cell reports 7 (6), 1940-1955, 2014 | 110 | 2014 |
| Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer F Al-Ejeh, PT Simpson, JM Sanus, K Klein, M Kalimutho, W Shi, ... Oncogenesis 3 (4), e100-e100, 2014 | 109 | 2014 |
| RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis CE Bond, DM McKeone, M Kalimutho, ML Bettington, SA Pearson, ... Oncotarget 7 (43), 70589, 2016 | 92 | 2016 |
| RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis CE Bond, DM McKeone, M Kalimutho, ML Bettington, SA Pearson, ... Oncotarget 7 (43), 70589, 2016 | 92 | 2016 |
| Patterns of genomic instability in breast cancer M Kalimutho, K Nones, S Srihari, PHG Duijf, N Waddell, KK Khanna Trends in pharmacological sciences 40 (3), 198-211, 2019 | 84 | 2019 |
| Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer PV Raninga, AC Lee, D Sinha, YY Shih, D Mittal, A Makhale, AL Bain, ... International journal of cancer 146 (1), 123-136, 2020 | 70 | 2020 |
| CEP 55 is a determinant of cell fate during perturbed mitosis in breast cancer M Kalimutho, D Sinha, J Jeffery, K Nones, S Srihari, WC Fernando, ... EMBO molecular medicine 10 (9), e8566, 2018 | 70 | 2018 |
| Cep55 overexpression causes male‐specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling D Sinha, M Kalimutho, J Bowles, AL Chan, DJ Merriner, AL Bain, ... The FASEB Journal 32 (9), 4984-4999, 2018 | 50 | 2018 |
| Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition PV Raninga, A Lee, D Sinha, L Dong, KK Datta, X Lu, P Kalita-de Croft, ... Theranostics 10 (12), 5259, 2020 | 43 | 2020 |
| Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma F Al-Ejeh, M Pajic, W Shi, M Kalimutho, M Miranda, AM Nagrial, A Chou, ... Clinical Cancer Research 20 (12), 3187-3197, 2014 | 41 | 2014 |
| Enhanced dependency of KRAS‐mutant colorectal cancer cells on RAD 51‐dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae M Kalimutho, AL Bain, B Mukherjee, P Nag, DM Nanayakkara, SK Harten, ... Molecular oncology 11 (5), 470-490, 2017 | 37 | 2017 |
Kum Kum KhannaProfessorVerified email at qimrberghofer.edu.au
